Skip to content
Simpler Grants

No. PAR-25-145 · National Institutes of Health

Open

Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)

grants.gov listing Full announcement (NOFO)
Dealbreakers No cost share required Audit: not stated
Not reimbursement-only
“Grant: A financial assistance mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.” — From the announcement
Award range
Not specified
Expected awards
Not specified
Application deadline
Jan 7, 2028
Posted
Nov 6, 2024
Last verified
Yesterday

At a glance

AI summary

This program funds basic, translational, and clinical research on cancer therapy-related adverse effects that become chronic, progressive, or delayed after treatment, including work to identify mechanisms, characterize clinical features, and develop or validate prevention or mitigation strategies. Eligible applicants include a wide range of organizations such as nonprofits, universities, governments, for-profits, tribal organizations, and foreign organizations, and foreign components of U.S. organizations are allowed. The announcement allows new and resubmission applications and accepts projects with or without clinical trials. Awards are not limited in size, the number of awards depends on NIH appropriations and meritorious applications, the maximum project period is 5 years, and no cost sharing is required.

AI-generated summary — verify against the announcement

What it funds

  • Education
  • Health
  • Research & Discovery
  • Patients & People with Health Conditions
  • Researchers & Scholars
  • Biomedical & Disease Research
Official description from grants.gov

The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative research projects designed to address adverse sequelae of cancer therapies that persist and become chronic comorbidities or develop as delayed posttreatment effects. This FOA supports basic, translational, and clinical research projects that seek to identify the mechanisms of therapy-induced adverse sequelae, clinically characterize the adverse sequelae, or translate the mechanistic understanding into therapeutic approaches to prevent or minimize the development of long-term sequelae. Research projects should focus on mechanistic studies with translational endpoints and longitudinal clinical phenotyping to identify and validate clinical endpoints (biomarkers, imaging, patient-reported outcomes, or combined elements) for future use in clinical trials that will evaluate the efficacy of interventions designed to prevent or reduce specific adverse sequelae.

Who can apply

  • City or township governments
  • County governments
  • For-profit organizations other than small businesses
  • Independent school districts
  • Native American tribal governments (Federally recognized)
  • Native American tribal organizations (other than Federally recognized)
  • Nonprofits with 501(c)(3) status (other than higher education)
  • Nonprofits without 501(c)(3) status (other than higher education)
  • Others
  • Private institutions of higher education
  • Public and State controlled institutions of higher education
  • Public housing authorities / Indian housing authorities
  • Small businesses
  • Special district governments
  • State governments
Geographic restriction None found in the announcement — likely nationwide

Program history

USASpending.gov

Assistance listing 93.393 · Cancer Cause and Prevention Research

Real awards this federal program has made — the whole assistance listing (93.393), not just this notice.

Fiscal year Awards Median award Middle half
FY 2026 (so far) 167 $596,996 $422,899 – $685,984
FY 2025 233 $743,438 $397,772 – $1,287,560
FY 2024 331 $1,232,605 $403,858 – $1,928,145
FY 2023 333 $1,580,141 $399,888 – $2,324,497
FY 2022 371 — —
FY 2021 317 — —

Dollar figures are based on the 1,000 most recent awards we store, not all 1,752 — award counts are complete.

Who wins it Higher education (1,176), Nonprofit (458), Business (49) of 1,752 awards — categories can overlap.
Top states NY (124) · CA (100) · MA (89) · TX (82) · NC (34)
Largest recent awards
  1. HEALTH RESEARCH, INC. $8,975,418 · FY 2023
  2. REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO, THE $7,529,016 · FY 2024
  3. WAKE FOREST UNIVERSITY HEALTH SCIENCES $7,411,948 · FY 2023
  4. VANDERBILT UNIVERSITY MEDICAL CENTER $7,120,874 · FY 2023
  5. REGENTS OF THE UNIVERSITY OF MINNESOTA $6,827,635 · FY 2023

Source: USASpending.gov · refreshed Aug 14, 2026